HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antithrombotic drugs for secondary stroke prophylaxis.

Abstract
Stroke is the third most common cause of adult mortality in the United States. Antithrombotic agents form the mainstay of stroke prevention. Aspirin produces a modest reduction in the risk of second stroke and is widely recommended for initial therapy. The thienopyridines ticlopidine and clopidogrel are alternatives for secondary prevention in patients who do not respond to or cannot take aspirin. They are no more effective than aspirin and have been associated with thrombotic thrombocytopenic purpura. The combination of aspirin and extended-release dipyridamole has several mechanisms of action and an additive effect on reducing stroke risk compared with either agent alone. A 2-fold increase in risk reduction and favorable safety profile suggest that the combination can serve as first-line prophylaxis against a second stroke.
AuthorsL C Pettigrew
JournalPharmacotherapy (Pharmacotherapy) Vol. 21 Issue 4 Pg. 452-63 (Apr 2001) ISSN: 0277-0008 [Print] United States
PMID11310519 (Publication Type: Journal Article, Review)
Chemical References
  • Fibrinolytic Agents
  • Dipyridamole
  • Aspirin
Topics
  • Adult
  • Aspirin (administration & dosage, therapeutic use)
  • Dipyridamole (administration & dosage, therapeutic use)
  • Drug Therapy, Combination
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Platelet Aggregation (drug effects)
  • Stroke (economics, prevention & control)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: